RRA
AKBA icon

Round Rock Advisors’s Akebia Therapeutics AKBA Stock Holding History

Round Rock Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-166,089
Closed -$231K – 320
2026
Q1 		$231K Hold
166,089
– – 0.04% 297
2025
Q4 		$267K Buy
166,089
+22,841
+16% +$47.8K 0.04% 288
2025
Q3 		$427K Buy
+143,248
New +$477K 0.07% 195

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Round Rock Advisors's AKBA Position: Q2 2026 in Review

Round Rock Advisors sold out of Akebia Therapeutics (AKBA) in Q2 2026, closing a stake of 166,089 shares — an estimated $231K sold.

Round Rock Advisors first reported a position in AKBA in Q3 2025 and held it in 3 quarters. The position peaked at $427K in Q3 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Round Rock Advisors reported no remaining Akebia Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Round Rock Advisors sold 166,089 Akebia Therapeutics shares in Q2 2026, an estimated $231K.
  • Round Rock Advisors first reported a position in Akebia Therapeutics in Q3 2025 and held it in 3 quarters.
  • Round Rock Advisors's Akebia Therapeutics position peaked at $427K in Q3 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Round Rock Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.